Arthrosi Therapeutics
Clinical trials sponsored by Arthrosi Therapeutics, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New gout drug shows promise in major trial Results expected Sep 2026 (estimated)
- New hope for tough gout: drug combo targets uric acid after other treatments fail Results expected Nov 2026 (estimated)
-
New gout drug shows promise in major trial
Disease control OngoingThis study tests a new medicine called AR882 to see if it can lower uric acid levels in people with gout. About 750 adults with gout will receive either AR882 or a placebo for 12 months. The main goal is to see if AR882 helps more patients reach a safe uric acid level and reduce …
Phase 3 • Sponsor: Arthrosi Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for tough gout: drug combo targets uric acid after other treatments fail
Disease control OngoingThis study tests a new drug called AR882, taken with a standard gout medication (XOI), in 15 people with severe, uncontrolled gout who have already failed uricase therapy. The goal is to see if the combination can lower uric acid levels and shrink painful uric acid crystal deposi…
Phase 2 • Sponsor: Arthrosi Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC